Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00776-7. [Epub ahead of print]

PMID:
31452081
2.

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M.

Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018.

3.

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.

J Neurol. 2019 Mar;266(3):707-716. doi: 10.1007/s00415-019-09193-4. Epub 2019 Jan 16.

PMID:
30649617
4.

Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study.

Artusi CA, Bortolani S, Merola A, Zibetti M, Busso M, De Mercanti S, Arnoffi P, Martinetto S, Gaidolfi E, Veltri A, Barbero P, Lopiano L.

Parkinsonism Relat Disord. 2019 May;62:231-235. doi: 10.1016/j.parkreldis.2018.11.003. Epub 2018 Nov 5.

PMID:
30442481
5.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M.

J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

6.

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.

Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Review.

PMID:
28641055
7.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT.

Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

PMID:
28290755
8.

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea.

Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M.

J Vis Exp. 2016 Nov 9;(117). doi: 10.3791/54606.

9.

Influence of cigarette smoking on ALS outcome: a population-based study.

Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Marinou K, Bottacchi E, Pisano F, Mora G, Mazzini L, Chiò A.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229-1233. doi: 10.1136/jnnp-2016-313793. Epub 2016 Sep 21.

PMID:
27656044
10.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Aug;3(4):e273.

11.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Barbero P, Busso M, Tinivella M, Artusi CA, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio' A, Durelli L, Clerico M.

J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

PMID:
26410746
12.

Heterozygous Deletion of KLHL1/ATX8OS at the SCA8 Locus Is Unlikely Associated With Cerebellar Impairment in Humans.

Mandrile G, Di Gregorio E, Goel H, Giachino D, De Mercanti S, Iudicello M, Rolando M, Losa S, De Marchi M, Brusco A.

Cerebellum. 2016 Apr;15(2):208-12. doi: 10.1007/s12311-015-0679-3. No abstract available.

13.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

14.

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M.

J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.

PMID:
25097195
15.

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, Cugnasco P, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Sideri R, Marinou K, Bottacchi E, Pisano F, Cantello R, Mazzini L, Mora G; Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis.

JAMA Neurol. 2014 Sep;71(9):1134-42. doi: 10.1001/jamaneurol.2014.1129.

16.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
17.

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group.

Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781 .

PMID:
19278300
18.

ALS patients and caregivers communication preferences and information seeking behaviour.

Chiò A, Montuschi A, Cammarosano S, De Mercanti S, Cavallo E, Ilardi A, Ghiglione P, Mutani R, Calvo A.

Eur J Neurol. 2008 Jan;15(1):55-60. Epub 2007 Nov 14.

PMID:
18005051

Supplemental Content

Loading ...
Support Center